• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (OP:PPCB)

10.40 UNCHANGED
Last Price Updated: 3:35 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
July 12, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions
July 05, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
June 24, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer
June 22, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
June 14, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly
June 01, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer
May 26, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
May 18, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Offers a Novel Way to Stop Cancer
May 11, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study
May 02, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment
April 13, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic
April 06, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office
March 22, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors
March 16, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year
February 23, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment
December 21, 2021
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP
December 14, 2021
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey
November 03, 2021
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes
May 17, 2021
From Propanc Biopharma, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  243.68
+6.19 (2.61%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap